An FDA panel meets Tuesday to consider pulling the diabetes drug Avandia from the market.
Dozens of studies have linked the former GlaxoSmithKline best-seller to an increased risk of heart attack.
Government scientists say studies conducted by the company are flawed and actually make the case against Avandia.
The panel will make its recommendation to the FDA after a two-day review of the drug's performance.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.